{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-010257","form_type":"8-K","ticker":"BHC","cik":"0000885590","company_name":"Bausch Health Companies Inc.","filed_at":"2024-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.169913+00:00","generated_at":"2026-05-31T19:25:36.130407+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bausch Health appoints Jean-Jacques Charhon as CFO, Aimee Lenar as EVP US Pharma","bullets":["Jean-Jacques Charhon named CFO effective Aug 19, 2024; base salary $700K, target bonus 60%, equity grants ~$3M.","Charhon receives one-time sign-on cash bonus of $300K and sign-on equity grant of $3.5M (50% RSUs, 50% PSUs).","Interim CFO John Barresi returns to SVP, Controller role; granted $350K retention RSU award vesting over 3 years.","Barresi's enhanced severance extended to Dec 31, 2025; bi-weekly $5K stipend extended to Sep 30, 2024.","Aimee Lenar joined Jul 15, 2024 as EVP US Pharma, leading Salix, Neurology, Generics, Market Access."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-010257","json":"https://secwatch.observer/filing/0000950103-24-010257.json","markdown":"https://secwatch.observer/filing/0000950103-24-010257.md","text":"https://secwatch.observer/filing/0000950103-24-010257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885590/000095010324010257/0000950103-24-010257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885590/000095010324010257/dp214678_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:25:36.130407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40496238f1","claim":"John S. Barresi changed role as Senior Vice President, Controller and Chief Accounting Officer at Bausch Health Companies Inc..","evidence_excerpt":"John S. Barresi, who has served as the Company’s interim Chief Financial Officer since October 2023, will no longer act in this capacity and will continue in his role as Senior Vice President, Controller and Chief Accounting Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885590/000095010324010257/0000950103-24-010257-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will no longer act in this capacity and will continue"},{"label":"Role","value":"Senior Vice President, Controller and Chief Accounting Officer"}]},{"claim_id":"85f624eeec","claim":"Jean-Jacques Charhon was appointed as Executive Vice President and Chief Financial Officer at Bausch Health Companies Inc..","evidence_excerpt":"On July 15, 2024, the Board of Directors (the “Board”) of Bausch Health Companies Inc. (the “Company”) appointed Jean-Jacques Charhon as the Company’s Executive Vice President and Chief Financial Officer, effective as of August 19, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885590/000095010324010257/0000950103-24-010257-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Financial Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}